Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee C Chang

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Contemporary Clinical Trials|December 21, 2018
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocolSanjay J Mathew, Samuel T Wilkinson, Murat Altinay, et al.
Molecular Psychiatry|October 5, 2018
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Molecular Psychiatry|January 9, 2019
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
The New England Journal of Medicine|May 24, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionAmit Anand, Sanjay J Mathew, Gerard Sanacora, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Contemporary Clinical Trials|December 21, 2018
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocolSanjay J Mathew, Samuel T Wilkinson, Murat Altinay, et al.
Molecular Psychiatry|October 5, 2018
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Molecular Psychiatry|January 9, 2019
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
The New England Journal of Medicine|May 24, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionAmit Anand, Sanjay J Mathew, Gerard Sanacora, et al.
Pageof 2